Tissue Plasminogen Activator Market, By Drug Type (Alteplase, Reteplase, Tenecteplase), By Application (Ischemic Stroke, Myocardial Infarction, Pulmonary Embolism, Thrombolysis, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Sep 2023

Code : CMI2469

Pages :141

Formats :

Excel and PDF

Industry : Biotechnology

Market News

Global Tissue Plasminogen Activator Market: Key Developments

In July 2021, Boehringer Ingelheim GmbH, a worldwide pharmaceutical company, announced its plan to initiate Phase III part of its Phase II/III TRISTARDS clinical study of alteplase to treat COVID-19 patients with acute respiratory distress syndrome (ARDS). The drug demonstrated a promising safety and effectiveness profile in an interim review of the study, which has completed the exploratory open-label Phase IIb phase with 62 patients.

In May 2021, Biogen Inc., a pharmaceutical company that focuses on neuroscience drugs, and TMS Co., Ltd., a clinical stage biotechnology company, announced that Biogen Inc. exercised its option to acquire TMS-007, a clinical-stage drug for acute ischemic stroke, from TMS Co., Ltd. The acquisition of TMS-007 by Biogen Inc. was based on favorable findings from a Phase 2a research. TMS-007 is a small molecule plasminogen activator with a unique hypothesized mode of action linked to dissolving blood clots and perhaps preventing local inflammation at the site of thrombosis.

In February 2020, Reliance Life Sciences Private Limited, a research-driven organization, launched three biosimilars to the market: interferon beta, reteplase, and human chorionic gonadotropin. Reteplase is a purified version of human tissue plasminogen activator that is used to treat myocardial infarction, ischemic stroke, and pulmonary embolism in the event of an emergency.